key: cord-0813296-pdt11yi2
authors: Thiede, Joshua M; Gress, Abigail R; Libby, Samuel D; Ronayne, Christine E; Matchett, William E; Noren, Brooke; Billings, Joanne L; Menachery, Vineet D; Langlois, Ryan A; Kline, Susan; Bold, Tyler D
title: Immune profiling reveals early disease trajectories associated with COVID-19 mortality: a sub-study from the ACTT-1 trial
date: 2021-01-21
journal: J Infect Dis
DOI: 10.1093/infdis/jiab035
sha: 41b08d4bf0c0d9332ca416f1dcb3362f87eccc0c
doc_id: 813296
cord_uid: pdt11yi2

COVID-19 outcomes are linked to host immune responses and may be impacted by antiviral therapy. We investigated antibody and cytokine responses in ACTT-1 study participants enrolled at our center. We studied serum specimens from 19 hospitalized adults with COVID-19 randomized to treatment with remdesivir or placebo. We assessed SARS-CoV-2 antibody responses and identified cytokine signatures using hierarchical clustering. We identified no clear immunologic trends attributable to remdesivir treatment. Seven subjects were initially seronegative at study enrollment, and all four deaths occurred in this group with more recent symptom onset. We identified three dominant cytokine signatures, demonstrating different disease trajectories.

The ACTT-1 clinical trial of remdesivir was the first double-blind, randomized, placebocontrolled trial in the United States to find a beneficial effect of antiviral therapy for COVID-19, shortening time to recovery in hospitalized adults [1] . The interplay between antiviral therapies like remdesivir and host immune responses to SARS-CoV-2 has not been explored. Serological assays quantitating both antibody binding and functional neutralization activity against SARS-CoV-2 positively correlate with disease severity [2, 3] . However, both rely on the timely development of pathogen-specific antibodies, which may be impacted by inhibition of viral replication [2, 4] . Several studies have investigated whether humoral responses may serve as biomarkers of disease outcome with mixed results [5, 6] . Similarly the impact of anti-viral therapy on cytokine responses is unknown. While others have identified cytokine signatures associated with disease trajectory, severity, and survival [7] [8] [9] , one hallmark of COVID-19 is the high degree of inter-person variability in immune parameters, consistent with the wide spectrum of disease manifestations and severity. We therefore aimed to define humoral immune responses and cytokine trajectories within our institutional ACTT-1 study cohort.

Our analyses suggest that absence of humoral immunity at the time of study enrollment was associated with a more aggressive immunologic trajectory and worse survival. Hierarchical clustering of multiplex serum cytokine concentrations over time revealed distinct immune signatures, confirming both the high degree of heterogeneity among COVID-19 patients but also demonstrating strong consistency in immune response over time within individuals.

A c c e p t e d M a n u s c r i p t 5

Of 1,063 subjects enrolled in ACTT-1, 31 were at the University of Minnesota Medical Center and Bethesda Hospital, MHealth Fairview Medical Center. Our site adhered to the ACTT-1 study protocol for consent and enrollment of subjects [1] , and was overseen by a central institutional review board at the University of Nebraska. Hospitalized individuals 18 years or older with symptoms consistent with COVID-19 and PCR-confirmed SARS-CoV-2 infection were included. All had either radiographic pulmonary infiltrate or hypoxemia (oxygen saturation ≤94% on room air). Subjects were randomized to receive a 10-day treatment course of either remdesivir or placebo while hospitalized. Of 31 subjects, 19 consented to collection of serum samples. Subject characteristics are in Table S1 .

Serum was collected and stored at -80°C for batch analysis. Pre-treatment (day 1) specimens were collected for all 19 subjects, post-treatment (day 11 or 15) specimens were collected for 13 subjects, and final (day 29) specimens were collected for 7 subjects.

Anti-SARS-CoV-2 serology was determined using ELISA kits from RayBiotech using nm). A nonlinear regression method was used to calculate the serum dilution that neutralized 50% of mNeonGreen fluorescence (NT 50 ) using Prism 8 (GraphPad). Each serum sample was tested in duplicate. Neutralization curves for all samples tested are presented in Figure S1 .

A commercial 48-plex human cytokine kit was purchased from EMD Millipore and run on a Luminex instrument (Bioplex 200) at the Cytokine Reference Laboratory at the University of Minnesota. Serum samples were run in duplicate and cytokine concentration values were interpolated from 5-parameter fitted standard curves. Two cytokines (IL-3, and MIP-1a) were undetectable across all samples tested and therefore excluded from all analyses. Hierarchical clustering and heatmap generation were accomplished using ComplexHeatmap package in R.

Each cytokine concentration was scaled and centered. Samples were initially clustered using an unsupervised hierarchical method, which identified three dominant immune signatures. Based on this analysis, final sample clustering was performed after manual assignment of each sample A c c e p t e d M a n u s c r i p t 7 to one of these three clusters. K-means algorithm was used to divide cytokines into two groups to identify early vs. late features of infection.

To longitudinally assess antibody responses, we performed ELISAs for nucleocapsid (N) and spike (S) RBD specific IgG, as well as live SARS-CoV-2 neutralization assays, calculating the serum titer that neutralized 50% (NT 50 ) of viral infection. We found a broad range of initial serologic values with some individuals presenting as seropositive on day 1 of enrollment, while others were seronegative ( Figure 1A ). We observed no clear association between treatment arm and serologic outcomes. Seven subjects were initially seronegative by neutralization assay (NT 50 <80), and 12 subjects seropositive (NT 50 >80). All subjects assessed at the post-treatment time points were seropositive by all assays ( Figure 1A ). Subjects who were initially seronegative for both S RBD and N, or who were seropositive for N alone, had significantly lower neutralization activity than individuals that were initially seropositive for both S RBD and N ( Figure S2A ). There was excellent agreement between ELISA and neutralization assay results for day 1 specimens, with strong positive associations between NT 50 and both S RBD IgG (Spearman r = 0.9736, Figure S2B ) or N IgG (Spearman r = 0.8740, not shown).

Of 19 subjects, all four who did not survive were seronegative for SARS-CoV-2 (S RBD and N IgG negative, and NT 50 <80) at the time of enrollment. The median survival duration for the seronegative group was 12 days vs 29 days for the seropositive group (p = 0.003, Figure   1B , Supplemental Table S2 ), and the median duration of hospitalization for the seronegative group was 34 vs 14.5 days in the seropositive group (p = 0.03, Supplemental Table S2 ).

Concordantly, there was a significant difference in neutralization activity between the survivors and those who died ( Figure 1C) , with a median NT 50 value among survivors of 1535 compared A c c e p t e d M a n u s c r i p t 8 to 37.81 in the deceased group (Table S2) . There was no association between initial seropositivity and other patient characteristics including sex, age, or study arm; however, the seronegative group was enriched for subjects with a more recent onset of symptoms when compared to the seropositive group (median 5 vs 9.5 days, Table S2 ). These findings suggest that individuals who are seronegative at the time of initial hospital evaluation for COVID-19 may represent a subgroup at higher risk of poor outcome, due to either a delayed onset of humoral immune responses, or a more aggressive disease trajectory.

To further explore the relationship between cytokine profile and patient characteristics, we performed unsupervised hierarchical clustering of 46 cytokines from 39 serum specimens longitudinally collected from our 19 subjects. Specimens clustered into three cytokine signatures characterized by high (cluster 3), moderate (cluster 2), and mild (cluster 1) overall cytokine expression ( Figure 2A ). These data are broadly similar to the cytokine signatures identified by others, with the hyperinflammatory cluster 3 comparing closely with clusters representing severe disease, characterized by the high expression of TNF-a, IL-6, and M-CSF [9] . Cluster 1 was consistent with cytokine signatures of either early or moderate disease and recovery. Samples from the 4 individuals who did not survive were found in each of the clusters. Among pre-or post-treatment samples, we also found no association between cytokine cluster and treatment arm. Notably, we observed a close relationship in cytokine signatures among samples taken from the same individual. Indeed, of the 14 individuals with more than one sample collected in our dataset, nine had multiple samples that clustered together despite their collection being temporally separated by 10-28 days (Figure 2A) . These results likely reflect the observed heterogenous spectrum of COVID-19 disease severity but reveal immunologic consistency over time within individuals.

Because our cytokine dataset revealed a high degree of individuality among subjects, we finally focused on each subject's disease trajectory over time, as marked by progression A c c e p t e d M a n u s c r i p t 9 between cytokine clusters. By comparing all subjects with initial samples localized to the same cluster, we identified three major trajectories for movement between clusters: stable, increasing, and decreasing ( Figure 2B ). Of the 14 subjects with more than one sample collected, only two (017 and 014) demonstrated an increasing trajectory over time, both starting from the mild disease cluster 1. Both of these individuals were initially seronegative and were enrolled after a brief duration of illness (4 and 5 days, respectively), suggestive of an aggressive disease trajectory. Eight subjects showed a stable progression over time. Two (015 and 011), both initially seronegative, remained in the most severe disease cluster. All subjects with stable disease trajectories remaining in less severe clusters 1 or 2 survived the infection, and only one of these was seronegative on day 1. These limited data suggest an association between the prompt initiation of pathogen-specific humoral immunity and a more stable, potentially less lethal disease course. Finally, four subjects had decreasing disease trajectories, suggesting a resolving infection, all of whom survived the disease. The individuality of our cytokine dataset as a whole suggests that, depending on a patient's immunologic status and timing of sample collection, a cytokine signature at a single timepoint may be insufficient to determine patient trajectory and prognosis.

Our study of immunologic characteristics of 19 hospitalized subjects with COVID-19 enrolled in the ACTT-1 trial revealed several key insights into the pathogenesis of this heterogenous disease. Within our small cohort, we observed that the absence of serum neutralization on enrollment was associated with worse patient outcomes, including worse 29-day survival and longer hospitalization duration among those surviving. These data suggest that initial antibody levels in hospitalized patients could provide valuable prognostic data for risk stratifying patients.

A c c e p t e d M a n u s c r i p t 10 While neutralization assays with live SARS-CoV-2 are resource-intensive, ELISA based methods could provide a suitable alternative in acute illness, where the correlation between antibody binding and functional activity is strong [13, 14] . Further, lower neutralization titer at enrollment was associated with a shorter duration of time from symptom onset to enrollment, suggesting a more rapid disease progression characterized by symptom progression that outpaces the initiation of adaptive immunity.

While larger studies have identified several cytokines as biomarkers of disease severity and outcome, in our smaller study, we did not identify any individual cytokines whose pre-or posttreatment values were strongly predictive of mortality (Table S3 and S4). This difference may reflect the limited power of our small sample size to detect these differences, in the context of substantial disease heterogeneity. Initial PDGF AA/AB serum levels were significantly higher among individuals who survived (Table S3) potentially identifying subjects with more effective adaptive immunity at the time of enrollment and a relatively benign disease trajectory.

While we did observe associations between mortality and both initial seronegativity and recency of symptom onset, we did not identify large differences in antibody or cytokine responses between remdesivir and placebo treatment groups. This may reflect the limited effect of initiating antiviral therapy on immune trajectories already in progress, or the limited power of our small dataset to detect these differences. Yet, our cytokine analyses add to the growing appreciation of the individuality of each patient's response to SARS-CoV-2 infection and disease trajectory, which may have substantial impact on the universality of biomarker interpretations [8] . A larger-scale analysis of serology, neutralization, and cytokine signature in 

We thank Allison Weyer

Remdesivir for the Treatment of Covid-19 -Final Report

Antibody responses to SARS-CoV-2 in patients with COVID-19

Serology assays to manage COVID-19. Science (80-. ). 2020

The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production

Sex differences in immune responses that underlie COVID-19 disease outcomes

Longitudinal analyses reveal immunological misfiring in severe COVID-19

A dynamic COVID-19 immune signature includes associations with poor prognosis

An inflammatory cytokine signature predicts COVID-19 severity and survival

SARS-CoV-2 neutralization and serology

An Infectious cDNA Clone of SARS-CoV-2

A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Antibody Responses and Clinical Outcomes in Adults Hospitalized With Severe Coronavirus Disease 2019 (COVID-19): A Post hoc Analysis of LOTUS China Trial

The authors declare no financial or otherwise beneficial conflicts of interest. This work was supported by National Institutes of Health T32AI055433 (JMT), T32HL774126 (WEM), and

A c c e p t e d M a n u s c r i p t 12